Безопасность применениягенно-инженерных биологическихпрепаратов при ревматоидном артрите
https://doi.org/10.14412/1996-7012-2010-587
Аннотация
Представлен обзор современных исследований, посвященных безопасности применения генно-инженерных биологических препаратов (ГИБП) у больных ревматоидным артритом. Указывается, что терапия ГИБП требует тщательного скрининга больных до
начала лечения для исключения инфекционных заболеваний (в том числе туберкулеза) или высокого риска развития инфекции (хронические язвы голени, сахарный диабет тяжелого течения, персистирующая легочная инфекция, наличие мочевого катетера), а
также онкологической патологии, тяжелых заболеваний внутренних органов. Следует учитывать также исходное состояние печени, кардиоваскулярный риск, наличие нейтропении в ответ на использование базисных противовоспалительных препаратов
(БПВП). Отмечено, что при правильном отборе больных и мониторинге возможных нежелательных явлений терапия ГИБП переносится не хуже, чем лечение БПВП.
начала лечения для исключения инфекционных заболеваний (в том числе туберкулеза) или высокого риска развития инфекции (хронические язвы голени, сахарный диабет тяжелого течения, персистирующая легочная инфекция, наличие мочевого катетера), а
также онкологической патологии, тяжелых заболеваний внутренних органов. Следует учитывать также исходное состояние печени, кардиоваскулярный риск, наличие нейтропении в ответ на использование базисных противовоспалительных препаратов
(БПВП). Отмечено, что при правильном отборе больных и мониторинге возможных нежелательных явлений терапия ГИБП переносится не хуже, чем лечение БПВП.
Об авторах
Наталья Владимировна ЧичасоваЕвгений Львович Насонов
Наталья Владимировна Чичасова
Евгений Львович Насонов
Литература
1. <div><p>Рациональная фармакотерапия ревматических заболеваний. Под ред. В.А. Насоновой и Е.Л. Насонова. М., Литтера, 2003;506 с.</p><p>Насонов Е.Л. Ревматоидный артрит - модель атеротромбоза. РМЖ 2005;13(8):509-12.</p><p>Riise T., Jacobsen B.K., Gran J.T. et al. Total mortality is increased in heumatoid arthritis. A 17- year prospective study. Clin Rheum 2002;20:123-7.</p><p>Smolen J., Van der Heijde D.M., StClair E.W. et al. Prediction of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from ASPIRE trial. Arthr Rheum 2006;54:702-10.</p><p>Maini R.N., Breedveld F.C., Kalden J.R. et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthr Rheum 2004;50:1051-65.</p><p>Breedveld F.C., Weisman M.N., Kavanaugh A.F. et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthr Rheum 2006;54:26-37.</p><p>Weinblatt M.E., Keystone E.C., Furst D.E. et al. Adalimumab a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthr Rheum 2003;48:35-45.</p><p>Emery P., Breedveld F.C., Hall S. et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet 2008;372:375-82.</p><p>Emery P., Fleischmann R., Filipowicz-Sosnovska A. et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of phase IIB randomized, double-blind, placebo-controlled, doseranging trial. Arthr Rheum 2006;54:1390-400.</p><p>Smolen J., Andre Beaulieu A., Rubbert-Roth A. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.</p><p>Genovese M.C., Schiff M., Luggen M. et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tomour necrosis factor therapy. Ann Rheum Dis 2008;67:547-54.</p><p>Khanna D., McMahon M., Furst D.E. Safety of tumour necrosis factor-alpha antagonist. Drug Safety 2004;27:307-24. 13.</p><p>Van Vollenchoven R.F., Siri D., Furie R. et al. Longterm safety and tolerability of Tocilizumab treatment in patients with rheumatoid arthritis and a mean treatment duration of 2.4 years. Arthr Rheum 2009;60(Suppl. 10):S731, ACR 2009, Presentation 1955. 14.</p><p>Vander Cruyssen B.J. et al. Four year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple DMARD treatment: long-term clinical effect and prediction of attrition. Arthr Rheum 2006;54(Suppl. 9):s234-5.</p><p>Лукина Г.В., Сигидин Я.А., Чичасова Н.В. и др. Применение моноклональных антител к фактору некроза опухоли (Ремикейд) при ревматоидном артрите: предварительные результаты. Тер арх 2003;5:9-12. 16.</p><p>Van Vollenchoven R.F., Emery P., Binham C.O. et al. Long-term safety of Rituximab: long-term followup of the RA clinical trials and retreatment population. Arthr Rheum 2009;60(Suppl. 10):S730 (abstr.1952).</p><p>Keystone E.C., Kavanaugh A.F., Sharp J.T. et al. Radiographic, clinical and functional outcomes of treatment with Adalimumab (a human anti-tumour necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthr Rheum 2004;50:1400-11. 18.</p><p>ENBREL Prescribing Information, Immunex Corporation, Seattle, Wash.U.S. Package Insert of Humira. 20.</p><p>Инструкция по применению препарата Ремикейд от 21.04.2006.</p><p>Westhovens R., Robles M., Ximenes A.D. et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognosis factors. Ann Rheum Dis 2009; 5 Jan, online, DoI:10.1136/ard.2008.101121</p><p>Emery P., Durez P., Dougados M. et al. Efficacy of Abatacept in delaying the development of rheumatoid arthritis (RA) in adult patients with undifferent inflammatory arthritis at high risk of developing RA. Ann Rheum Dis 2008;67(Suppl. II):89.</p><p>Frederick W. Treatment for Rheumatoid Arthritis and the Risk of Hospitalization for Pneumonia. Arthr Rheum 2006;54:628-34.</p><p>Dixon W.G., Symmons P.M., Lunt M. et al. Serious infection following anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Lessons from interpreting data from observational studies. Arthr Rheum 2007;56:2904-86.</p><p>Mariette X. Clinical case and are the objective futures that may drive the choice between different anti TNF 〈 Wyeth Dermatology and Rheumatology Summit. Amsterdam, 2008.</p><p>Strand V., Yasici Y. Inrerleukin 6 inhibition. Tolerability profile and clinical implication. Bull NYU Hosp Joint Dis 2007;65(Suppl. 1):S21-4.</p><p>Насонов Е.Л., Козлов Р.С., Якушин С.Б. Инфекционные осложнения терапии блокаторами фактора некроза опухоли: предупрежден - значит, вооружен. Клин микробиол антимикробн химиотер 2006;8:1-11. 28.</p><p>RemicadeR Prescribing Information. Centocor Inc 2006.</p><p>Symmons D.P., Silman A.J. The world of biologics. Lupus 2006;15:122-6.</p><p>Calabrese L.H., Molloy E.S. Rituximab and PML risk - informed decisions needed! Nature Reviews Rheumatol 2009;5(10):528-9.</p><p>Calabrese L.H., Molloy E.S., Huang D. et al. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthr Rheum 2007;56:2116-8.</p><p>Molloy E.S., Calabrese L.H. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimm Rev 2008;8:144-6.</p><p>Curtis J.R. et al. Tumor necrosis factor-〈 antagonists increase risk of hospitalization with a bacterial infection among rheumatoid arthritis patients. Arthr Rheum 2006;54(Suppl. 9):S517.</p><p>Balanescu A. et al. Tuberculosis in rheumatoid arthritis patients treated with infliximab - the Romanian experience. Arthr Rheum 2006;54(Suppl. 9):S405.</p><p>Gomez-Reino J.J., Carmona L., Descalzo M.A. Tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthr Care & Researc 2007;57(5):756-71.</p><p>Tubach F., Salmon D., Ravaud P. et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The threeyear prospective french research axed tolerance of biotherapy registry. Arthr Rheum 2009;60:1884-94.</p><p>Favalli E.G., Desiati F., Atzeni F. et al. Serious infections during anti-TNF〈 treatment in rheumatoid arthritis patients. Autoimm Rev 2009;8:266-73.</p><p>Schiff M.H., Burmester G.R., Kent J.D. et al. Safety analysis of adalimumab (Humira) in global clinical trials and US post marketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889-94.</p><p>Burmester G.R., Mease P., Dijkmans B.A.C. et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009;68:1863-9.</p><p>Emery P. Biography of Tocilizumab for rheumatoid arthritis. NowPharma LTD, UK, 2009, 58 pp.</p><p>Cohen S.D., Emery P., Greenwald M.W. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of multicenter, randomized, double-blind, placebo-contrilled, phase III trial evaluating primary efficacy and safety at twenty four weeks. Arthr Rheum 2006;54:2793-806.</p><p>Latorrel M.C., Valero Y.S. Rituximab in patients with rheumatoid arthritis ans disseminated and latent tuberculosis: long term follow up. 21 Rheumatology, Clinica de Artritis y Rehabilitacion, Bogota; 2 Rheumatology, Clinica de Artritis y Rehabilitacion, Bogota, Colombia, 2009 [SAT0061].</p><p>Smitten A., Simon T., Qi K. et al. Hospitalized infections in the Abatacept RA cliniczl development program: an epidemiological assessment with > 10,000 person-years of exposure. Arthr Rheum 2008;58:Iss.9(Suppl.), poster 12.</p><p>Dabbous O. et al. Impact of age on outcomes of Japanese patients with rheumatoid arthritis treated with infliximab: the post marketing surveillance trial. Arthr Rheum 2006;54(Suppl. 9), S421.</p><p>Saag K.S., Teng G.G., Patkar N.M. et al. American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. Arthr Care & Research 2008;59:762-84.</p><p>Furst D.E., Keystone E.C., Kirkman B. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008;67:iii2-25.</p><p>Lipsky P.E., van der Heide D.M., StClair E.W. et al. Infliximab and metotrexate in treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.</p><p>Smitten A.L., Simon T.A., Hochberg M.C. et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthr Res Ther 2008;10:R45.</p><p>Chakravarty E.F., Genovese M.C. Assocations between rheumatoid arthritis and malignancy. Rheum Dis Clin North M. 2004;30:271-84.</p><p>Mellemljaer L., Linet M.S., Gridley G. et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-7.</p><p>Framklin J., Lunt M., Bunn D. et al. Influence of inflammatory polyarthritis on cancer incidence and survival. Arthr Rheum 2007;56:2886-95.</p><p>Bongartz T., Sutton A.J., Sweeting M.J. et al. Anti-TNF antibody terapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.</p><p>Dixon W., Silman A. Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the metaanalysis by Bongartz et al. Arthr Res Ther 2006;8:111.</p><p>Wolfe F., Michaud K. Biologic treatment of the rheumatoid arthritis and the risk of malignancy. Arthr Rheum 2007;56:2886-95.</p><p>Askling J., Fored C.M., Drandt L. et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with timour nacrosis factor antagonists. Ann Rheum Dis 2005;64:1421-6.</p><p>Geborek P., Bladstrom A., Turesson C. et al. Tumour nacrosis factor blokers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703.</p><p>Weinblatt M.E., Genovese M.C., Kremer J.M. et al. Safety and efficacy of Etanercept (Enbrel) treatment in North American patients with earle and long-standing rheumatoid arthritis: 1 year of clinical experience. ACR presentation, 2008, abstr. 1007.</p><p>Wolfe F., Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19562 patients during 89710 person-years of observation. Arthr Rheum 2007;56:1433-9.</p><p>Baecklund E., Iliadou A., Askling J. et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthr Rheum 2006;54:692-701.</p><p>Keystone E.C. Safety of biologic therapies - an update. J Rheumatol 2005;74:8-12.</p><p>Simon T.A. et al. Standardized incidence ratios of malignancies from published literature of Abatacept-treated patients compared with the general population. Ann Rheum Dis 2008; DOI: 10.1136 / ard. 2008.097527 on line.</p><p>Smitten A. et al. Standardized incidence ratios of lymphoma from published Abatacept literature compared with non-biological DMARD RA cohorts. Arthr Rheum 2008;59(Suppl. 9):S787. 63.</p><p>Infliximab. Summary of product characteristics. http://www.emea.europa.eu 64.</p><p>Adalimumab. Summary of product characteristics. http://www.emea.europa.eu</p><p>Anderson P.J. Tumor necrosis factor inhibitors: clinical implications of their immunogenicity profiles. Semin Arthr Rheum 2005;34(Suppl. I):19-22.</p><p>Robinson W.H., Genovese M.C., Moreland L.W. Demyelinating and neurologic events reported in association with tumor necrosis factor antagonist. Arthr Rheum 2001;44:1977-83.</p><p>Genovese M.C., McKay J.D., Nasonov E.L. et al. Interleukin-6 receptor inhibition with Tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the Tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthr Rheum 2008;58:2968-80.</p><p>Еmery P., Keystone E., Tony H.P. et al. IL-6 receptor inhibition with tocilizumab improved treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biological: result from 24-week multicenter randomized placebo- controlled trial. Ann Rheum Dis 2008. doi: 10.1136/ ard.2008.092932 online 69.</p><p>Диагностика туберкулезной инфекции при планировании и проведении терапии блокаторами ФНО〈. Пособие для врачей. под ред. акад. РАМН, главного специалиста эксперта-фтизиатра Минздравсоцразвития России, директора НИИ фтизиопульмонологии ММА им. И.М.</p><p>Сеченова М.И.Перельмана и директора ГУ Института ревматологии РАМН акад. РАМН, проф. Е.Л. Насонова. М.,2008.</p></div><br />
Рецензия
Для цитирования:
Чичасова Н.В., Насонов Е.Л., Чичасова Н.В., Насонов Е.Л. Безопасность применениягенно-инженерных биологическихпрепаратов при ревматоидном артрите. Современная ревматология. 2010;4(1):46-58. https://doi.org/10.14412/1996-7012-2010-587
For citation:
Chichasova N.V., Nasonov E.L., Chichasova N.V., Nasonov E.L. Safety of using genetic engineering biological agents in rheumatoid arthritis. Modern Rheumatology Journal. 2010;4(1):46-58. (In Russ.) https://doi.org/10.14412/1996-7012-2010-587
Просмотров: 1441
Послать статью по эл. почте 